keyword
MENU ▼
Read by QxMD icon Read
search

HOPE-3

keyword
https://www.readbyqxmd.com/read/27722961/treatment-of-hypertension-which-goal-for-which-patient
#1
Faiçal Jarraya
Hypertension remains the most important risk factor for cardiovascular disease. If antihypertensive drugs choice is well guided today, blood pressure (BP) target still a subject of controversies. Residual risk is matter of debate and the lower- the better dogma is come back again regarding to data reported from recent trials. The J curve, reason for European Society of Hypertension Guidelines reappraisal in 2009, is criticized by recent data. The one goal (<140/90 mmHg) fit 90 mmg 90 mmHg) fit all should be adapted as a personalized goal guided by evidence generated by randomized controlled trials...
October 9, 2016: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27639873/isolated-systolic-hypertension-an-update-after-sprint
#2
REVIEW
Chirag Bavishi, Sangita Goel, Franz H Messerli
Isolated systolic hypertension is the most common hemodynamic form of hypertension in the elderly. With a rapidly aging population, the prevalence of hypertension, particularly isolated systolic hypertension, is expected to increase substantially. This phenomenon of increasing systolic pressure in the elderly is believed to be secondary to pathophysiological changes of aging as well as modifiable risk factors. Isolated systolic hypertension is associated with substantial mortality and morbidity, particularly of cerebrovascular disease...
December 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27619924/should-patients-with-cardiovascular-risk-factors-receive-intensive-treatment-of-hypertension-to-120-80-mm%C3%A2-hg-target-an-antagonist-view-from-the-hope-3-trial-heart-outcomes-evaluation-3
#3
https://www.readbyqxmd.com/read/27604076/comparing-the-sprint-and-the-hope-3-blood-pressure-trial
#4
Paul K Whelton, David M Reboussin, Lawrence J Fine
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27604060/assessing-cardiovascular-risk-to-guide-hypertension-diagnosis-and-treatment
#5
Ann Marie Navar, Michael J Pencina, Eric D Peterson
Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other trials, such as Heart Outcomes Prevention Evaluation-3 (HOPE-3), did not find consistent benefit. How to incorporate these results into the treatment of those with elevated SBP in the general population is not clear. Objectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United States and to explore the cardiovascular disease (CVD) risk profiles of various populations with elevated SBP...
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27602555/the-sprint-and-the-hope-3-trial-in-the-context-of-other-blood-pressure-lowering-trials
#6
Salim Yusuf, Eva Lonn
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27598921/-pharmacological-primary-prevention-of-myocardial-infarction-stroke-and-death-a-possible-task
#7
Christian Keller, Jochen Müller-Ehmsen
The HOPE-3-Trial investigated the effect of primary prevention on cardio- and neurovascular events in patients without known atherosclerotic disease, but with intermediate risk. In a factorial design Rosuvastatin 10 mg, Candesartan 16 mg/HCT 12.5 mg or both were compared with placebo. Rosuvastatin effectively lowered LDL-cholesterol and the rate of cardio- and neurovascular complications with a NNT of approximately 500/year without detectable effect on mortalitiy. Candesartan 16 mg/HCT 12.5 mg did not influence any endpoint, however, the predefined subgroup of patients with hypertension level I had a benefit...
September 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27521103/clinical-trials-of-intensive-versus-less-intensive-control-of-hypertension-hope-or-hype
#8
Christina M Wyatt, Glenn M Chertow
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials...
September 2016: Kidney International
https://www.readbyqxmd.com/read/27508808/-op-lb-02-08-the-effect-of-blood-pressure-lowering-on-mortality-and-cardiovascular-disease-is-modified-by-baseline-systolic-blood-pressure-systematic-review-meta-analysis
#9
M Brunström, B Carlberg
OBJECTIVE: To assess the effect of blood pressure lowering treatment on the risk of death and cardiovascular disease at different blood pressure levels. DESIGN AND METHOD: We used data from a previous systematic review and meta-analysis of blood pressure lowering treatment, adding the results from the recently published HOPE-3 trial. The previous review standardised risk ratio and study weights according to blood pressure lowering, which has previously been associated with deranged results...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27485846/-koment%C3%A3-%C3%A5-ke-%C3%A4-l%C3%A3-nku-hope-3-statins-lower-cv-events-in-intermediate-chd-risk-patients
#10
Jiří Widimský
UNLABELLED: The HOPE-3 study focused on identifying the significance of the polypill and mini-polypill in broad clinical practice, including individuals of different gender without cardiovascular diseases with an intermediate risk of cardiovascular diseases. The authors were interested in the question whether people from various antropologhy groups including not only white people but also other antropologhy groups - the blacks, people of Asian and South American origin and more covering 6 continents, would respond in a similar way...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27292823/hope-3-and-sprint-two-landmark-trials-with-different-outcomes
#11
EDITORIAL
John B Kostis, Suzanne Oparil
No abstract text is available yet for this article.
June 2016: Journal of the American Society of Hypertension: JASH
https://www.readbyqxmd.com/read/27181913/prevention-hope-3-trial-targeting-bp-and-ldl-c-in-at-risk-patients
#12
John T Wilkins, Donald M Lloyd-Jones
No abstract text is available yet for this article.
May 16, 2016: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/27160151/hope-3-sprint-value-and-a-meta-analysis-of-trials-in-patients-with-diabetes-support-treatment-of-hypertension-to-a-target-below-140%C3%A2-mmhg
#13
Sverre E Kjeldsen, Thomas Hedner, Krzysztof Narkiewicz
No abstract text is available yet for this article.
June 2016: Blood Pressure
https://www.readbyqxmd.com/read/27041480/blood-pressure-lowering-in-intermediate-risk-persons-without-cardiovascular-disease
#14
RANDOMIZED CONTROLLED TRIAL
Eva M Lonn, Jackie Bosch, Patricio López-Jaramillo, Jun Zhu, Lisheng Liu, Prem Pais, Rafael Diaz, Denis Xavier, Karen Sliwa, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Katalin Keltai, Matyas Keltai, Irina Chazova, Ron J G Peters, Claes Held, Khalid Yusoff, Basil S Lewis, Petr Jansky, Alexander Parkhomenko, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Lawrence A Leiter, Dora I Molina, Robert McKelvie, Janice Pogue, Joanne Wilkinson, Hyejung Jung, Gilles Dagenais, Salim Yusuf
BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk and with lower blood pressure is unclear. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12...
May 26, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27040132/cholesterol-lowering-in-intermediate-risk-persons-without-cardiovascular-disease
#15
RANDOMIZED CONTROLLED TRIAL
Salim Yusuf, Jackie Bosch, Gilles Dagenais, Jun Zhu, Denis Xavier, Lisheng Liu, Prem Pais, Patricio López-Jaramillo, Lawrence A Leiter, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Alexander Parkhomenko, Katalin Keltai, Matyas Keltai, Karen Sliwa, Ron J G Peters, Claes Held, Irina Chazova, Khalid Yusoff, Basil S Lewis, Petr Jansky, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Gregorio Sanchez-Vallejo, Robert McKelvie, Janice Pogue, Hyejung Jung, Peggy Gao, Rafael Diaz, Eva Lonn
BACKGROUND: Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo...
May 26, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27039945/blood-pressure-and-cholesterol-lowering-in-persons-without-cardiovascular-disease
#16
RANDOMIZED CONTROLLED TRIAL
Salim Yusuf, Eva Lonn, Prem Pais, Jackie Bosch, Patricio López-Jaramillo, Jun Zhu, Denis Xavier, Alvaro Avezum, Lawrence A Leiter, Leopoldo S Piegas, Alexander Parkhomenko, Matyas Keltai, Katalin Keltai, Karen Sliwa, Irina Chazova, Ron J G Peters, Claes Held, Khalid Yusoff, Basil S Lewis, Petr Jansky, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Jose L Accini, Robert McKelvie, Janice Pogue, Hyejung Jung, Lisheng Liu, Rafael Diaz, Antonio Dans, Gilles Dagenais
BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. METHODS: In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12...
May 26, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26791016/recovery-in-mind-perspectives-from-postgraduate-psychiatric-trainees
#17
Matthew Gambino, Anthony Pavlo, David A Ross
OBJECTIVE: The authors assessed psychiatric trainees' understanding of recovery-oriented care, a therapeutic philosophy with varied meanings but wide purchase in contemporary mental health policy. METHODS: Four cohorts of residents were presented with a clinical vignette as part of a written curricular evaluation and asked what it would mean to engage the patient from a recovery-oriented perspective. Responses were subjected to qualitative analysis, with the analysts examining each cohort independently, then meeting to discuss their findings and build consensus on the most pertinent themes...
June 2016: Academic Psychiatry
https://www.readbyqxmd.com/read/26577896/tribulations-of-recent-cardiology-trials-the-audacity-of-hope-and-hope-3
#18
EDITORIAL
David D Waters, Katherine Hsin-Yu Chau
No abstract text is available yet for this article.
March 2016: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/26481083/novel-approaches-in-primary-cardiovascular-disease-prevention-the-hope-3-trial-rationale-design-and-participants-baseline-characteristics
#19
RANDOMIZED CONTROLLED TRIAL
Eva Lonn, Jackie Bosch, Janice Pogue, Alvaro Avezum, Irina Chazova, Antonio Dans, Rafael Diaz, George J Fodor, Claes Held, Petr Jansky, Matyas Keltai, Katalin Keltai, Kamlesh Kunti, Jae-Hyung Kim, Lawrence Leiter, Basil Lewis, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Alexandr Parkhomenko, Ron J G Peters, Leopoldo S Piegas, Christopher M Reid, Karen Sliwa, William D Toff, John Varigos, Denis Xavier, Khalid Yusoff, Jun Zhu, Gilles Dagenais, Salim Yusuf
BACKGROUND: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drugs and BP-lowering drugs, reducing major cardiovascular (CV) events by 20%-30% within 5 years in high-risk individuals. However, there are limited data in lower-risk populations. The Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial is evaluating whether cholesterol lowering with a statin drug, BP lowering with low doses of 2 antihypertensive agents, and their combination safely reduce major CV events in individuals at intermediate risk who have had no previous vascular events and have average cholesterol and BP levels...
March 2016: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/26029142/patients-experiences-of-maintaining-mental-well-being-and-hope-within-motor-neuron-disease-a-thematic-synthesis
#20
REVIEW
Andrew Soundy, Nicola Condon
Research is required that can synthesize the experiences of patients with Motor Neuron Disease (MND). One value of being able to do this is to understand the psychological experiences and processes involved in maintaining mental well-being and hope. A qualitative thematic synthesis of studies was undertaken. Studies were electronically searched from inception until June 2014. Twenty-nine studies with 342 (175 male) unique individuals with MND were identified. Five themes were identified: (1)The effects of the disease on interactions, relationships, roles and meaningful activities, (2) Responses that relate to the expression of hope, (3) Factors which disable hope, (4) Factors which enable hope, and (5) Cognitive and Practical adaptation that enabled hope, control and coping...
2015: Frontiers in Psychology
keyword
keyword
111857
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"